(VIANEWS) – The NASDAQ opens in less than five hours and Novavax‘s pre-market value is already 5.79% up.
Novavax’s last close was $8.46, 89.1% under its 52-week high of $77.65.
The last session, NASDAQ finished with Novavax (NVAX) rising 11.46% to $8.46. NASDAQ rose 0.76% to $12,087.96, following the last session’s upward trend on what was a somewhat bullish trend trading session.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Moving Average
Novavax’s worth is under its 50-day moving average of $8.59 and way below its 200-day moving average of $24.87.
Revenue Growth
Year-on-year quarterly revenue growth grew by 310.7%, now sitting on 1.85B for the twelve trailing months.
More news about Novavax (NVAX).
